The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst
: So just had a multiparter, a very simple one, though. So on sales force, just wondering what the productivity trends were that you're
assuming in the fourth quarter guidance. I guess just like -- just for that context, the 9,000 providers added in the third quarter, then
access is still, I guess, 50% of pre-COVID. And then similar to that, I guess, there's a broad range of companies trying to break into
screening or even different cancers, just obviously the benefit from your sales force and network of provider relationships really
helped. So would you ever consider maybe offering a portion of your sales force on like a temporary contract basis maybe to
competitor and whether it's screening or, again, monitoring things like that?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 02, 2021 / 9:00PM, EXAS.OQ - Q3 2021 Exact Sciences Corp Earnings Call
And finally, I just think this is an important question to kind of ask and to think about, with all these pipeline tests being launched
in '23 and '25, that kind of time frame, there's a lot of long-term potential, obviously, what's going to be the most exciting, I guess,
think about Exact between now and then from an investor perspective?
|
